Kidney Transplant Infection, SARS-CoV Infection
Conditions
Keywords
Vaccination, Humoral, Cellular
Brief summary
None of the vaccines approved, or in clinical trials, have so far been tested on transplanted patients. If they produce an immune response to the Spike protein of SARS-CoV-2 it is unknown how long the protective immunity will last. Not all immune responses are equal. The investigators will quantify immune cell subsets with flow and mass cytometry analyses to describe the phenotype of responding immune cells, including specific T cells. If not already established, patient human Leukocyte antigen (HLA) genotypes will be typed. In order to compare the immune responses with healthy individuals a control group of hospital employees will be included and sampled before and after vaccination according to the same time schedules as the kidney transplanted patients.
Detailed description
Kidney transplanted patients with post-transplant follow-up visits at the national transplant center in Norway will be included before they are SARS-CoV-2 vaccinated. As a control group the investigators will include blood samples from healthy volunteers (hospital employees) that receive vaccine as first line health care workers. Baseline blood samples will be obtained before vaccination. The vaccination will be performed according to the national procedures and not necessarily by the hospital. Following vaccination, all patients and controls will have blood drawn 7-10 days as well as 4-6 weeks after the second dose. Depending on the results of the immunity testing the patients and controls may be invited to additional blood sampling up or at specific time points to two years following vaccination. At each blood sampling and at the time of both vaccinations the systemic exposure of tacrolimus will be assessed in kidney transplanted patients. All samples will be analyzed with validated assays for SARS-CoV-2 immunoglobulin G (IgG) (anti-receptor binding domain (RBD) spike protein) using ELISA, flow cytometry bead arrays and SARS-CoV-2 neutralization assays or comparable techniques. Cells will be analyzed by flow and mass cytometry for activation and phenotype markers, and with functional assays for responsiveness (e.g. proliferation and cytokine production). Samples will be HLA-typed if HLA-genotype if not already established.
Interventions
SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
Sponsors
Oslo University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients transplanted with a kidney (only) at least 6 months before vaccination OR healthy volunteer first line health care workers at OUS. * Age of 18 years or older (also for controls). * Standard immunological risk at transplantation (i.e. no donor specific HLA antibodies (DSA)) and not performed an ABO blood-type-incompatible transplantation. * No treatment for rejection episodes the last 6 months before inclusion. * Immunosuppressive therapy including tacrolimus, mycophenolate and prednisolone. * Stable graft-function the last 6 months. * S-creatinine \< 200 μmol/L (also for controls). * Signed informed consent to participate in the study (also for controls).
Exclusion criteria
* Three or more previous transplantations. * Hemoglobin level below 10 g/dL (also for control). * Leukopenia defined as total lymphocyte count \< 2 X 109 (also for controls). * Previous treatment with anti-thymocyte antibodies (ATG) or rituximab.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cellular immunological response | 1.5 months | IgG antibodies against SARS-CoV-2 spike protein above assay limit of positive sample. |
| Humoral immunological response | 1.5 months | T-cell reactivity against SARS-CoV-2 spike protein, including known mutation in the spike protein. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaccine related side effects | 6 months | Adverse drug reactions that have a reasonable relation to the vaccination, as assessed by the investigator |
Countries
Norway
Outcome results
None listed